Analysis of Nonlinear and Nonsteady State Hepatic Extraction with the Dispersion Model Using the Finite Difference Method

No abstract is available for this paper.

• Publication year

  1998

• Venue

  Journal of pharmacokinetics and biopharmaceutics

• Publication date

  1998-10-01

• Fields of study

  Medicine, Chemistry, Engineering

• Identifiers
  DOI 10.1023/A:1023294632129PMID 10205768
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Analysis of Nonlinear Hepatic Clearance of a Cyclopentapeptide, BQ-123, with the Multiple Indicator Dilution Method Using the Dispersion Model

  2004cited by this paper
• A note on the interpretation of tracer dispersion in the liver.

  1997cited by this paper
• Efficient numerical methods for nonlinear-facilitated transport and exchange in a blood-tissue exchange unit

  1997cited by this paper
• Hepatobiliary transport mechanism for the cyclopentapeptide endothelin antagonist BQ-123.

  1997cited by this paper
• Carrier-mediated active transport of BQ-123, a peptidic endothelin antagonist, into rat hepatocytes.

  1996cited by this paper
• The endothelin receptor is a major determinant for the nonlinear tissue distribution of the endothelin antagonist BQ-123.

  1996cited by this paper
• Accuracy of numerical inversion of Laplace transforms for pharmacokinetic parameter estimation.

  1995cited by this paper
• Hepatobiliary secretion of organic compounds; molecular mechanisms of membrane transport.

  1995cited by this paper
• An understanding of flow- and diffusion-limited vs. Carrier-mediated hepatic transport: A simulation study

  1995cited by this paper
• Different relationships between cellular ATP and hepatic uptake among taurocholate, cholate, and organic anions.

  1993cited by this paper
• Na(+)-independent multispecific anion transporter mediates active transport of pravastatin into rat liver.

  1993cited by this paper
• Models of hepatic drug elimination.

  1992influential reference
• NeXTSTEP Programming: STEP ONE: Object-Oriented Applications

  1992cited by this paper
• Enalaprilat handling by the kidney: barrier-limited cell entry.

  1992cited by this paper
• Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor.

  1992cited by this paper
• Effect of perfusion rate on the local disposition of cefixime in liver perfusion system based on two-compartment dispersion model.

  1991cited by this paper
• Carrier-mediated transport in the hepatic distribution and elimination of drugs, with special reference to the category of organic cations

  1990cited by this paper
• Kinetic analysis of cerebrovascular transport based on indicator diffusion technique.

  1989cited by this paper
• Two-compartment dispersion model for analysis of organ perfusion system of drugs by fast inverse laplace transform (FILT)

  1989cited by this paper
• Multispecificity of Na+-dependent taurocholate uptake in basolateral (sinusoidal) rat liver plasma membrane vesicles.

  1989cited by this paper
• A nonlinear least squares program, MULTI(FILT), based on fast inverse Laplace transform for microcomputers.

  1989cited by this paper
• Availability predictions by hepatic elimination models for Michaelis-Menten kinetics

  1989influential reference
• Dynamic determination of kinetic parameters for the interaction between polypeptide hormones and cell-surface receptors in the perfused rat liver by the multiple-indicator dilution method.

  1988influential reference
• Models of hepatic elimination: Comparison of stochastic models to describe residence time distributions and to predict the influence of drug distribution, enzyme heterogeneity, and systemic recycling on hepatic elimination

  1988influential reference
• On the relation between extended forms of the sinusoidal perfusion and of the convection-dispersion models of hepatic elimination.

  1987influential reference
• Effect of albumin on hepatic uptake of warfarin in normal and analbuminemic mutant rats: Analysis by multiple indicator dilution method

  1986cited by this paper
• An analysis program MULTI(ELS) based on extended nonlinear least squares method for microcomputers.

  1986cited by this paper
• A dispersion model of hepatic elimination: 1. Formulation of the model and bolus considerations

  1986influential reference
• Hepatic elimination--dispersion model.

  1985cited by this paper
• Dissociation from albumin: a potentially rate-limiting step in the clearance of substances by the liver.

  1985cited by this paper
• Lung serotonin uptake kinetics from indicator-dilution and constant-infusion methods.

  1984cited by this paper
• Effects of saturating metabolic uptake on space profiles and tracer kinetics.

  1983cited by this paper
• A mathematical model of indicator extraction by the pulmonary endothelium via saturation kinetics

  1982influential reference
• Residence time distributions in systems governed by the dispersion equation

  1981cited by this paper
• A pharmacokinetic analysis program (multi) for microcomputer.

  1981cited by this paper
• Hepatic transport kinetics and plasma disappearance curves: distributed modeling versus conventional approach.

  1978cited by this paper
• Hepatic elimination of flowing substrates: the distributed model.

  1978cited by this paper
• Hepatic clearance of drugs. I. Theoretical considerations of a “well-stirred” model and a “parallel tube” model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance

  1977influential reference
• Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance.

  1977cited by this paper
• Enzymatic elimination of substrates flowing through the intact liver.

  1976cited by this paper
• A new look at the statistical model identification

  1974cited by this paper
• Clearance concepts in pharmacokinetics

  1973influential reference
• Metabolism of propranolol by rat liver microsomes and its inhibition by phenothiazine and tricyclic antidepressant drugs.

  1971cited by this paper
• Capillary Exchange Modeling: Barrier-Limited and Flow-Limited Distribution

  1970cited by this paper
• Circulatory pathways in the rat liver as revealed by P32 chromic phosphate colloid uptake in the isolated perfused liver preparation.

  1956cited by this paper

• Quantitative Analysis of the Effect of Gastrointestinal Water Dynamics on Oral Drug Absorption using a Physiologically Based Integrated Liquid and Intestinal Absorption Drug (ILIAD) Pharmacokinetic Model.

  2026cites this paper
• Optimizing oral 3-hydroxybutyrate dosage using pharmacokinetic model to improve cognitive function and mood in healthy subjects

  2025cites this paper
• Fully dissolved glucose-responsive insulin delivery system based on a self-immolative insulin prodrug and glucose oxidase

  2025cites this paper
• ABCC4 polymorphism indirectly reduces systemic exposure to a capecitabine metabolite 5′‐deoxy‐5‐fluorouridine in Japanese subjects

  2025cites this paper
• Drug-drug interaction between trastuzumab emtansine (T-DM1) and orally administered tacrolimus in a patient and in rats.

  2025cites this paper
• Effect of obesity on pharmacokinetics of transdermal fentanyl: Single-center retrospective study and animal study.

  2024cites this paper
• Effect of changes in skin properties due to diabetes mellitus on the titration period of transdermal fentanyl: single-center retrospective study and diabetic animal model study

  2024cites this paper
• Beyond the basics: A deep dive into parameter estimation for advanced PBPK and QSP models.

  2024cites this paper
• Elucidating nonlinear pharmacokinetics of telmisartan: Integration of target‐mediated drug disposition and OATP1B3‐mediated hepatic uptake in a physiologically based model

  2024cites this paper
• Quantitative Analysis of Gastrointestinal Water Dynamics by Means of a Physiologically Based Fluid Kinetic Model

  2023cites this paper
• Physiologically‐based pharmacokinetic model‐based translation of OATP1B‐mediated drug–drug interactions from coproporphyrin I to probe drugs

  2022cites this paper
• Experimental and Modeling Evidence Supporting the Trans-Inhibition Mechanism for Preincubation Time-Dependent, Long-Lasting Inhibition of Organic Anion Transporting Polypeptide 1B1 by Cyclosporine A

  2022cites this paper
• Significance of Basal Membrane Permeability of Epithelial Cells in Predicting Intestinal Drug Absorption

  2022cites this paper
• A physiologically based pharmacokinetic and pharmacodynamic model for disposition of FF-10832.

  2022cites this paper
• Robust physiologically based pharmacokinetic model of rifampicin for predicting drug–drug interactions via P‐glycoprotein induction and inhibition in the intestine, liver, and kidney

  2022cites this paper
• Effect of Cyclosporin A and Impact of Dose Staggering on OATP1B1/1B3 Endogenous Substrates and Drug Probes for Assessing Clinical Drug Interactions

  2022cites this paper
• 3CL Protease Inhibitors with an Electrophilic Arylketone Moiety as Anti-SARS-CoV-2 Agents.

  2021cites this paper
• Maternal and Fetal Pharmacokinetic Analysis of Cannabidiol during Pregnancy in Mice

  2021influential citation
• A New Intestinal Model for Analysis of Drug Absorption and Interactions Considering Physiological Translocation of Contents

  2021cites this paper
• Model Analysis of the Apparent Saturation Kinetics of Purine Nucleobase Uptake in Cells co-Expressing Transporter and Metabolic Enzyme

  2021cites this paper
• Lack of Drug–Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers

  2020cites this paper
• Implementing PRED Subroutine of NONMEM for Versatile Pharmacokinetic Analysis using Fast Inversion of Laplace Transform (FILT).

  2020cites this paper
• Quantitative analysis of the effect of controlled-release formulation on nonlinear gastrointestinal absorption of P-glycoprotein substrate talinolol using physiologically based pharmacokinetic absorption model

  2020cites this paper
• Evaluation of hepatic uptake of OATP1B substrates by short term-cultured plated human hepatocytes: Comparison with isolated suspended hepatocytes.

  2020cites this paper
• Cell-to-Medium Concentration Ratio Overshoot in the Uptake of Statins by Human Hepatocytes in Suspension, but Not in Monolayer: Kinetic Analysis Suggesting a Partial Loss of Functional OATP1Bs

  2020cites this paper
• Mathematical modeling analysis of hepatic uric acid disposition using human sandwich-cultured hepatocytes.

  2020cites this paper
• Pharmacokinetics of edoxaban in EGFR-mutated non-small cell lung cancer patients with venous thromboembolism.

  2020cites this paper
• Physiologically‐Based Pharmacokinetic Modeling Analysis for Quantitative Prediction of Renal Transporter–Mediated Interactions Between Metformin and Cimetidine

  2019cites this paper
• Microdosing clinical study to clarify pharmacokinetic and pharmacogenetic characteristics of atorvastatin in Japanese hypercholesterolemic patients.

  2019cites this paper
• Expanded Physiologically‐Based Pharmacokinetic Model of Rifampicin for Predicting Interactions With Drugs and an Endogenous Biomarker via Complex Mechanisms Including Organic Anion Transporting Polypeptide 1B Induction

  2019cites this paper
• PBPK Modeling of Coproporphyrin I as an Endogenous Biomarker for Drug Interactions Involving Inhibition of Hepatic OATP1B1 and OATP1B3

  2018cites this paper
• Physiologically Based Pharmacokinetic Modeling of Bosentan Identifies the Saturable Hepatic Uptake As a Major Contributor to Its Nonlinear Pharmacokinetics

  2018cites this paper
• Effect of the active ingredient of Kaempferia parviflora, 5,7-dimethoxyflavone, on the pharmacokinetics of midazolam

  2018cites this paper
• Comprehensive PBPK Model of Rifampicin for Quantitative Prediction of Complex Drug‐Drug Interactions: CYP3A/2C9 Induction and OATP Inhibition Effects

  2018cites this paper
• Evaluation of Alteration in Hepatic and Intestinal BCRP Function In Vivo from ABCG2 c.421C>A Polymorphism Based on PBPK Analysis of Rosuvastatin

  2018cites this paper
• Quantitative Analysis of Complex Drug-Drug Interactions between Cerivastatin and Metabolism/Transport Inhibitors Using Physiologically Based Pharmacokinetic Modeling

  2018cites this paper
• Preferential Cleavage of a Tripeptide Linkage by Enzymes on Renal Brush Border Membrane To Reduce Renal Radioactivity Levels of Radiolabeled Antibody Fragments.

  2018cites this paper
• A Novel Method to Estimate Long‐Term Chronological Changes From Fragmented Observations in Disease Progression

  2018cites this paper
• Abundant migration of midazolam and 1’-hydroxymidazolam into the fetal brain following midazolam administration to pregnant mice in the second trimester

  2018cites this paper
• Extrapolation of In Vivo Hepatic Clearance from In Vitro Uptake Clearance by Suspended Human Hepatocytes (IVIVE) for Anionic Drugs with High Binding to Human Albumin: Improvement of IVIVE by Considering the “Albumin-Mediated” Hepatic Uptake Mechanism Based on the Facilitated-Dissociation Model

  2018cites this paper
• Quantitative Analyses of the Influence of Parameters Governing Rate-Determining Process of Hepatic Elimination of Drugs on the Magnitudes of Drug-Drug Interactions via Hepatic OATPs and CYP3A Using Physiologically Based Pharmacokinetic Models.

  2017cites this paper
• Notable Drug–Drug Interaction Between Etizolam and Itraconazole in Poor Metabolizers of Cytochrome P450 2C19

  2017cites this paper
• Estimation of the Contribution of CYP2C8 and CYP3A4 in Repaglinide Metabolism by Human Liver Microsomes Under Various Buffer Conditions.

  2017cites this paper
• Analysis of Nonlinear Pharmacokinetics of a Highly Albumin-Bound Compound: Contribution of Albumin-Mediated Hepatic Uptake Mechanism.

  2017cites this paper
• Utilization of Gastrointestinal Simulator, an in Vivo Predictive Dissolution Methodology, Coupled with Computational Approach To Forecast Oral Absorption of Dipyridamole.

  2017cites this paper
• Determination of kinetic parameters for 123-I thyroid uptake in healthy Japanese

  2017cites this paper
• Quantitative Analysis of Complex Drug-Drug Interactions Between Repaglinide and Cyclosporin A/Gemfibrozil Using Physiologically Based Pharmacokinetic Models With In Vitro Transporter/Enzyme Inhibition Data.

  2017cites this paper
• Involvement of organic cation transporter 3 (Oct3/Slc22a3) in the bioavailability and pharmacokinetics of antidiabetic metformin in mice.

  2016cites this paper
• Quantitative Analyses of Hepatic OATP‐Mediated Interactions Between Statins and Inhibitors Using PBPK Modeling With a Parameter Optimization Method

  2016cites this paper
• Key determinants of the circulatory exposure of organic anions: differences in hepatic uptake between multidrug resistance-associated protein 2 (Mrp2)-deficient rats and wild-type rats

  2015influential citation
• Analysis of the Disposition of a Novel p38 MAPK Inhibitor, AKP-001, and Its Metabolites in Rats with a Simple Physiologically Based Pharmacokinetic Model

  2015cites this paper
• Quantitative Analysis of the ABCG2 c.421C>A Polymorphism Effect on In Vivo Transport Activity of Breast Cancer Resistance Protein (BCRP) Using an Intestinal Absorption Model.

  2015cites this paper
• A New Physiologically Based Pharmacokinetic Model for the Prediction of Gastrointestinal Drug Absorption: Translocation Model

  2015cites this paper
• Mechanisms of lower maintenance dose of tacrolimus in obese patients.

  2014cites this paper
• Analysis of the repaglinide concentration increase produced by gemfibrozil and itraconazole based on the inhibition of the hepatic uptake transporter and metabolic enzymes (292.2)

  2014cites this paper
• Analysis of the Repaglinide Concentration Increase Produced by Gemfibrozil and Itraconazole Based on the Inhibition of the Hepatic Uptake Transporter and Metabolic Enzymes

  2013cites this paper
• DMD049460 362..371

  2013cites this paper
• Bayesian estimation of pharmacokinetic parameters of vancomycin in patients with decreasing renal function.

  2012cites this paper
• MASS TRANSFER MODELING OF HEPATIC DRUG ELIMINATION USING LOCAL VOLUME AVERAGING APPROACH

  2012cites this paper
• Identification of the Rate‐Determining Process in the Hepatic Clearance of Atorvastatin in a Clinical Cassette Microdosing Study

  2011cites this paper
• Importance of Taylor dispersion in pharmacokinetic and multiple indicator dilution modelling.

  2009cites this paper
• Analysis of Nonlinear Hepatic Clearance of a Cyclopentapeptide, BQ-123, with the Multiple Indicator Dilution Method Using the Dispersion Model

  2004cites this paper
• A Compartmental Model of Hepatic Disposition Kinetics: 1. Model Development and Application to Linear Kinetics

  2004influential citation
• Analysis methods and recent advances in nonlinear pharmacokinetics from in vitro through in loci to in vivo.

  2004cites this paper
• Clinical Pharmacokinetic/Pharmacodynamic and Physiologically based Pharmacokinetic Modeling in New Drug Development: The Capecitabine Experience

  2003cites this paper
• Whole Body Pharmacokinetic Models

  2003cites this paper
• A Dispersion Model for Cellular Signal Transduction Cascades

  2002cites this paper
• A Novel Hepatic-Targeting System for Therapeutic Cytokines That Delivers to the Hepatic Asialoglycoprotein Receptor, but Avoids Receptor-Mediated Endocytosis

  2002cites this paper
• Investigation of 5‐FU disposition after oral administration of capecitabine, a triple‐prodrug of 5‐FU, using a physiologically based pharmacokinetic model in a human cancer xenograft model: comparison of the simulated 5‐FU exposures in the tumour tissue between human and xenograft model

  2001cites this paper
• Quantitative Evaluation of Capacity-Limited Hepatobiliary Transport Based on Hepatocellular Diffusion Model by MULTI(FEM)

  2001cites this paper
• A Whole-Body Physiologically Based Pharmacokinetic Model Incorporating Dispersion Concepts: Short and Long Time Characteristics

  2001cites this paper
• A Physiologically Based Pharmacokinetic Analysis of Capecitabine, a Triple Prodrug of 5-FU, in Humans: The Mechanism for Tumor-Selective Accumulation of 5-FU

  2001cites this paper
• Dose-dependency in local disposition of 5-fluorouracil under non-steady-state condition in rat liver.

  2000cites this paper
• Problems of mixed boundary conditions for convection-dispersion models in the analysis of local pharmacokinetics.

  2000cites this paper
• Notes on the inverse Gaussian distribution and choice of boundary conditions for the dispersion model in the analysis of local pharmacokinetics.

  1999cites this paper